Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1991 1
2006 3
2007 3
2008 2
2009 1
2011 1
2012 6
2013 4
2014 9
2015 13
2016 15
2017 10
2018 7
2019 18
2020 19
2021 19
2022 11
2023 22
2024 6
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
T-large granular lymphocytic leukemia.
Park SH, Lee YJ, Kim Y, Kim HK, Lim JH, Jo JC. Park SH, et al. Among authors: jo jc. Blood Res. 2023 Apr 30;58(S1):S52-S57. doi: 10.5045/br.2023.2023037. Epub 2023 Apr 7. Blood Res. 2023. PMID: 37026382 Free PMC article. Review.
Plasmacytoid dendritic cell neoplasms.
Lee YJ, Kim Y, Park SH, Jo JC. Lee YJ, et al. Among authors: jo jc. Blood Res. 2023 Apr 30;58(S1):90-95. doi: 10.5045/br.2023.2023052. Blood Res. 2023. PMID: 37105563 Free PMC article. Review.
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. Nat Cancer. 2025. PMID: 40097657 Free PMC article. Clinical Trial.
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Zhang Y, Patel RP, Kim KH, Cho H, Jo JC, Jeong SH, Oh SY, Choi YS, Kim SH, Lee JH, Angelos M, Guruprasad P, Cohen I, Ugwuanyi O, Lee YG, Pajarillo R, Cho JH, Carturan A, Paruzzo L, Ghilardi G, Wang M, Kim S, Kim SM, Lee HJ, Park JH, Cui L, Lee TB, Hwang IS, Lee YH, Lee YJ, Porazzi P, Liu D, Lee Y, Kim JH, Lee JS, Yoon DH, Chung J, Ruella M. Zhang Y, et al. Among authors: jo jc. Mol Cancer. 2023 Dec 9;22(1):200. doi: 10.1186/s12943-023-01886-9. Mol Cancer. 2023. PMID: 38066564 Free PMC article.
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Nat Cancer. 2025 May;6(5):907. doi: 10.1038/s43018-025-00967-6. Nat Cancer. 2025. PMID: 40240622 Free PMC article. No abstract available.
Comprehensive clinico-genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm.
Lee JH, Oh SY, Lee TG, Lee ST, Kim N, Pak MG, Yoon SS, Koh Y, Byun JM, Yoon DH, Jo JC, Yang DH, Ahn SY, Eom HS, Lee H, Lee JY, Won JH, Yhim HY, Lee HS, Kim WS, Park GS, Shin S, Kim SJ. Lee JH, et al. Among authors: jo jc. Br J Haematol. 2025 Apr;206(4):1228-1232. doi: 10.1111/bjh.20022. Epub 2025 Mar 10. Br J Haematol. 2025. PMID: 40065083 No abstract available.
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.
Jung SH, Koh Y, Kim MK, Kim JS, Moon JH, Min CK, Yoon DH, Yoon SS, Lee JJ, Hong CM, Kang KW, Kwon J, Kim KH, Kim DS, Kim SY, Kim SH, Kim YR, Do YR, Mun YC, Park SS, Park YH, Shin HJ, Eom HS, Yoon SE, Hwang SM, Lee WS, Lee MW, Yi JH, Lee JY, Lee JH, Lee HS, Lim SN, Lim J, Yhim HY, Chang YH, Jo JC, Cho J, Cho H, Choi YS, Cho HJ, Ahn A, Choi JH, Kim HJ, Kim K. Jung SH, et al. Among authors: jo jc. Blood Res. 2025 Feb 4;60(1):9. doi: 10.1007/s44313-025-00055-9. Blood Res. 2025. PMID: 39903326 Free PMC article. Review.
154 results